FENC - NASDAQ
Fennec Pharmaceuticals Inc.
$9.35
-6.3%Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
At a Glance
Live Snapshotfenc
Total Liabilities
Last Annual Value
35.02M
3-Year CAGR
6%
5-Year CAGR
72%
10-Year CAGR
54%
Fennec Pharmaceuticals Inc. Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Fennec Pharmaceuticals Inc. NASDAQ:FENC | 35.02M | -3.1% | 39.4% | 56.3% | |
 Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | 51.48M | 23.7% | -9.5% | N/A | |
 Black Diamond Therapeutics, Inc. NASDAQ:BDTX | 30.80M | -9.7% | -9.9% | N/A | |
 Assembly Biosciences, Inc. NASDAQ:ASMB | 50.84M | -19.0% | 18.1% | 10.8% | |
 Immuneering Corporation NASDAQ:IMRX | 13.50M | 4.0% | 4.7% | N/A | |
 SELLAS Life Sciences Group, Inc. NASDAQ:SLS | 7.47M | -19.3% | 4.2% | -14.8% | |
 Sagimet Biosciences Inc. NASDAQ:SGMT | 5.10M | -3.4% | -52.8% | N/A | |
 Entrada Therapeutics, Inc. NASDAQ:TRDA | 71.25M | -32.0% | 58.5% | N/A | |
 Zura Bio Limited NASDAQ:ZURA | 12.41M | -16.5% | 3.7% | N/A | |
 Caribou Biosciences, Inc. NASDAQ:CRBU | 53.19M | -5.9% | -0.5% | N/A | |
 Cartesian Therapeutics, Inc. NASDAQ:RNAC | 422.65M | -17.2% | 25.2% | 28.5% |
Fennec Pharmaceuticals Inc. Fair Value Envelope
Related Guides
Continue your FENC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.